LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

Sotera Health Announces Fourth-Quarter and Full-Year 2023 Earnings Release Date

February 15, 2024 | Last Trade: US$11.38 0.23 -1.98

CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2023 before the market opens on Tuesday, February 27, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.

To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live webcast of the conference call can be accessed at this link or via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health, along with the accompanying materials. A replay of the webcast will be available later in the day on February 27th.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Contacts
Jason Peterson
Vice President & Treasurer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.

Kristin Gibbs
Chief Marketing Officer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page